ER is also a strong predictor for effectiveness of anti-estrogen therapies; 5 years of adjuvant tamoxifen was found to be associated with 12.9–14.9% absolute decrease in 15-year cancer recurrence for women with ER+ cancers, but there was no apparent effect in those with ER-poor disease (RR 0.97, 95% confidence interval 0.88–1.07) [24]. The gene discussed is ESR1; the disease is cancer.